Focus: Kailera Therapeutics is a San Diego-based biotech company focused on peptide and small molecule therapeutics for metabolic diseases, particularly obesity. The company is actively advancing multiple clinical programs with a concentrated pipeline in the high-growth obesity treatment market.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Stable — net +4 jobs in 30d
9 added, 5 removed. Backfill posture.
Kailera offers meaningful career upside in a hot therapeutic area with active clinical momentum, but lack of financial transparency and pipeline depth warrant diligence on funding runway before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Kailera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kailera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Kailera Therapeutics, Inc.'s (NASDAQ:KLRA) Lock-Up Period Will End on October 14th - MarketBeat
Kailera Therapeutics, Inc.'s (NASDAQ:KLRA) Lock-Up Period Will End on October 14th MarketBeat
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting - The Manila Times
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting The Manila Times
An obesity shot showed similar drug levels after injection in the arm, thigh or abdomen. - stocktitan.net
An obesity shot showed similar drug levels after injection in the arm, thigh or abdomen. stocktitan.net
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting - GlobeNewswire
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting GlobeNewswire
Kailera Therapeutics (KLRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KLRA - MarketBeat
Kailera Therapeutics (KLRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KLRA MarketBeat
Kailera Therapeutics Announces Completion of Enrollment in - GlobeNewswire
Kailera Therapeutics Announces Completion of Enrollment in GlobeNewswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo